Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

FPA Crescent Fund 2026 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (FPA Crescent Fund)

Primary Source Intelligence • Q3 2026 Letter Analysis

FPA Crescent Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, FPA Crescent Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+1.48%

YTD+7.03%

Annualized+10.2%

Positioning StanceCONSTRUCTIVE

Market CapAll Cap

GeographyUS, Global

Digest Analysis

Quick Take

"Driven by contributions from core holdings like Alphabet and Analog Devices, while initiating new positions in healthcare, SMIDs, and TIPS yielding north of 3% real."

Executive Summary

FPA Crescent Fund - Institutional Class gained 1.48% net of fees in Q3 2026 and 10.34% net of fees over the trailing twelve-month period. For the trailing twelve months, the fund captured 61.7% of the MSCI ACWI return of 16.75% while maintaining an average net risk exposure of 64.0%. Net risk exposure ended the quarter at 66.5%, up from 63.3% in Q2 2026, driven by a common stock long exposure of 62.7%, common short exposure of -0.5%, long credit exposure of 1.3%, and other assets of 3.0%. The fund maintained significant dry powder, deploying capital into short-term U.S. Treasuries with yields near 5% and initiating positions in TIPS with real yields above 3%. From a macroeconomic perspective, the managers highlighted opportunities created by the higher interest rate regime in government debt, while noting that corporate credit spreads remain relatively tight versus Treasuries. Management observed that the rapid rise in interest rates is likely to trigger stress somewhere within credit markets, establishing a disciplined posture to deploy capital once dislocations arise. Consequently, the fund trimmed exposures to beneficiaries of the artificial intelligence ecosystem while selectively identifying value in neglected market segments. Portfolio activity reflected selective capital deployment across both domestic and international equities. The managers introduced new positions in healthcare via Boston Scientific and HCA Healthcare, while adding small- and mid-cap holdings including Core & Main, Fluidra, and JBT Marel. Key trailing twelve-month performance contributors included Alphabet, Analog Devices, and Samsung C&T, whereas Prosus, Charter Communications, and Jefferies detracted from returns amid company-specific and cyclical headwinds.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

65%

CautiousHigh

Moderate (65%)

Management displays moderate conviction across a diversified global portfolio of common stocks, credit, and government paper, with its top ten holdings representing 23.7% of total assets. Position sizing remains disciplined, with the largest exposure at 4.8% in Alphabet and several single-name additions sized between 0.2% and 0.5%. While the managers actively trimmed winning AI positions and selectively initiated SMID and healthcare names, their cautious tone on credit and general market pricing tempered outright aggressive sizing.

Growth Outlook

50%

BearishBullish

Neutral (50%)

The managers project a neutral, balanced stance on broader equity and debt markets, avoiding excessive enthusiasm or extreme pessimism. They express skepticism over tight corporate credit spreads given rapid rate increases, but simultaneously find attractive risk-adjusted yields in government obligations like 5% short-term Treasuries and 3%+ real yield TIPS. Overall, their outlook reflects patience, selective fundamental positioning, and waiting for market mispricings.

Risk Appetite

55%

DefensiveAggressive

Balanced (55%)

Risk posture is measured and balanced, as demonstrated by a net risk exposure of 66.5% against a five-year historical average of 69.9%. The fund holds substantial cash and government paper yielding close to 5%, avoiding aggressive high-yield credit due to narrow spreads. Risk assets are concentrated in resilient, cash-generative equities, complemented by selective shorts and TIPS.

Capital Deployment

60%

De-riskingDeploying

Net Neutral (60%)

Net risk exposure rose modestly from 63.3% in Q2 to 66.5% in Q3, reflecting net capital deployment into new equities and inflation-protected securities. Although the fund completely exited positions such as Broadcom, Diageo, and Marriott, it established stakes in Boston Scientific, HCA Healthcare, and several SMID holdings alongside a 1.5% allocation to TIPS.

Forward Guidance

70%

CautiousExpansionary

Expansionary (70%)

The management team explicitly indicates that it is building positions across several new investments that offer attractive long-term return potential at sensible valuations. While they pruned richly valued AI names, they are actively allocating fresh capital to healthcare and domestic and international SMIDs. They also maintain dry powder to aggressively deploy capital should rising rates spark credit market distress.

Language Signal

60%

BearishBullish

Balanced (60%)

Directional language balances positive commentary regarding specific corporate earnings, margin expansions, and attractive yields against words of caution regarding market pricing. Favorable terms like 'benefited', 'strengthening demand', 'record revenue', and 'attractive long-term return potential' outweigh cautionary phrasing around 'competitive pressure', 'execution risk', and 'stress somewhere in the credit market'.

Perceived Risk

65%

Low RiskElevated

Elevated Risk (65%)

The managers emphasize macroeconomic and credit vulnerabilities, explicitly warning that rapid interest rate increases are likely to induce systemic or localized stress across credit markets. They highlight heightened competition in telecom, elevated leverage risks, and tight credit spreads that fail to compensate investors for prevailing interest rate risks.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

Opportunities are selectively distributed across specific niches rather than broad asset classes. While corporate credit offers poor compensation due to tight spreads, the team identified attractive opportunities in short-term Treasuries, TIPS, healthcare additions, and SMID-cap equities. The manager notes patience is required, signaling that compelling broad-market valuations remain limited.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

Management emphasizes a multi-year investment horizon, focusing on businesses capable of long-term compounding and tangible book value growth through full economic cycles. Commentary highlights patience in allowing thesis drivers to unfold over multi-year periods, with historical performance evaluated across decades and full market cycles.